WASHINGTON – FDA epidemiologist David Graham has insisted for years that regulators should remove from the U.S. market GlaxoSmithKline plc's Type II diabetes drug Avandia (rosiglitazone), and a new study demonstrating the medicine is tied to an increased risk of stroke, heart failure and death has given him more ammunition to wage that battle. (BioWorld Today)

WASHINGTON – Although the Supreme Court Monday ruled that two businessmen's method of hedging risks in commodities was too abstract to be patentable, the justices said the so-called machine-or-transformation test is not the sole test for determining the patentability of all business methods – an opinion many are praising as leaving the door open for innovation. (BioWorld Today)